OVERALL GUIDELINE OBJECTIVE

This guideline aims to outline the four pillars for routine care for women of childbearing age and their families relating to:

• the prevention of new HIV cases, TB cases, syphilis cases, and other infections 
• the prevention of unintended pregnancies
• the prevention of vertical transmission of HIV, syphilis, and other infections, and 
• the care and treatment of the women living with, and their children exposed to HIV, syphilis and other infections

The National Drug Policy makes provision for an Essential Drugs Program (EDP), which is a key component in promoting rational medicines use. Each treatment guideline in the Paediatric Hospital Level Standard Treatment Guidelines (STGs) and Essential Medicines List (EML) has been designed as a progression in care from the current Primary Health Care (PHC) STGs and EML. In addition, where a referral is recommended, the relevant medicines have either been reviewed and included on the Tertiary level EML, or are in the process of being reviewed.

Who needs to be screened? The criteria for offering a Pap Smear to asymptomatic women: 

• between 30 and 50 years old
• HIV negative
• Gynecologically asymptomatic 
• older than 50, if never screened before

presentation slides 

Darunavir (DRV) and Ritonavir (RTV)-Paediatric Dosing Chart Version: 2022

A differentiated approach to care aims to strengthen linkage, adherence and retention using a patient-centred approach throughout the treatment cascade. This is globally known as Differentiated Service Delivery (DSD) while in South Africa is termed Differentiated Models of Care (DMOC).

Integrated Management of Childhood Illness  Chart Booklet 2022

The 2023 ART guideline introduces simplified ART provision and harmonised methods of management of children, adolescents and adults, 
as well as pregnant women living with HIV/AIDS, TB and other common opportunistic infections. 

The guidelines also provide guidance on the use of Dolutegravir (DTG) dispersible tablets for children from 3kg and 4 weeks old. 

These guidelines have been revised with the Differentiated Models of Care SOPs to ensure simultaneous consideration and alignment of clinical,
 adherence and service delivery updates.

The fifth NSP for HIV, TB and STIs launches at a time when the COVID-19 epidemic has affected access and the provision of services and solutions for HIV, TB and STIs and amplified inequalities. Consequently, this NSP outlines comprehensive multi-sectoral strategic objectives and priority interventions to be carried out to get the HIV, TB and STI response on track to eliminate these diseases as public health threats by 2030.